KR102262882B1 - 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들 - Google Patents

표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들 Download PDF

Info

Publication number
KR102262882B1
KR102262882B1 KR1020157017224A KR20157017224A KR102262882B1 KR 102262882 B1 KR102262882 B1 KR 102262882B1 KR 1020157017224 A KR1020157017224 A KR 1020157017224A KR 20157017224 A KR20157017224 A KR 20157017224A KR 102262882 B1 KR102262882 B1 KR 102262882B1
Authority
KR
South Korea
Prior art keywords
gly gly
gly
seq
ser
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157017224A
Other languages
English (en)
Korean (ko)
Other versions
KR20150088317A (ko
Inventor
미카 아오야기-샤버
테레사 마가렛 크리스티안슨
멜리타 드보르자크-이웰
다니엘 제이. 벤트
시농 롱
조나단 레보위츠
다니엘 솔로몬 골드
Original Assignee
바이오마린 파머수티컬 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오마린 파머수티컬 인크. filed Critical 바이오마린 파머수티컬 인크.
Priority to KR1020217017007A priority Critical patent/KR102385392B1/ko
Publication of KR20150088317A publication Critical patent/KR20150088317A/ko
Application granted granted Critical
Publication of KR102262882B1 publication Critical patent/KR102262882B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020157017224A 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들 Active KR102262882B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217017007A KR102385392B1 (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261730378P 2012-11-27 2012-11-27
US61/730,378 2012-11-27
US201361788968P 2013-03-15 2013-03-15
US61/788,968 2013-03-15
PCT/US2013/072287 WO2014085621A1 (en) 2012-11-27 2013-11-27 Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217017007A Division KR102385392B1 (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들

Publications (2)

Publication Number Publication Date
KR20150088317A KR20150088317A (ko) 2015-07-31
KR102262882B1 true KR102262882B1 (ko) 2021-06-10

Family

ID=49753532

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020157017224A Active KR102262882B1 (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들
KR1020227011416A Active KR102521039B1 (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들
KR1020237012007A Ceased KR20230054482A (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들
KR1020217017007A Active KR102385392B1 (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020227011416A Active KR102521039B1 (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들
KR1020237012007A Ceased KR20230054482A (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들
KR1020217017007A Active KR102385392B1 (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들

Country Status (26)

Country Link
US (8) US9376480B2 (enExample)
EP (2) EP2925776B1 (enExample)
JP (2) JP6831176B2 (enExample)
KR (4) KR102262882B1 (enExample)
CN (1) CN104822701B (enExample)
AR (1) AR093626A1 (enExample)
AU (1) AU2013352184B2 (enExample)
BR (1) BR112015012152B1 (enExample)
CA (1) CA2892146A1 (enExample)
CL (1) CL2015001371A1 (enExample)
CY (1) CY1122555T1 (enExample)
DK (2) DK2925776T3 (enExample)
ES (2) ES2729997T3 (enExample)
HR (2) HRP20181351T1 (enExample)
HU (2) HUE039334T2 (enExample)
IL (3) IL238824B (enExample)
LT (1) LT3115372T (enExample)
MX (2) MX367024B (enExample)
PL (2) PL3115372T3 (enExample)
PT (2) PT3115372T (enExample)
RS (1) RS58916B1 (enExample)
RU (1) RU2680581C2 (enExample)
SI (1) SI3115372T1 (enExample)
TW (2) TWI626250B (enExample)
WO (1) WO2014085621A1 (enExample)
ZA (1) ZA201503509B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170698T1 (hr) * 2008-05-07 2017-09-22 Biomarin Pharmaceutical Inc. Lizosomski usmjereni peptidi i njihove uporabe
HUE039334T2 (hu) 2012-11-27 2018-12-28 Biomarin Pharm Inc Célzott terápiás lizoszómális enzim fúziós fehérjék és azok alkalmazásai
HK1222093A1 (zh) * 2013-05-15 2017-06-23 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
JP6623213B2 (ja) * 2014-08-11 2019-12-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド リソソーム酵素に融合したマンノース−６−リン酸含有ペプチド
EP3197503A4 (en) * 2014-09-25 2018-05-16 The General Hospital Corporation Cell-based targeted delivery of pseudonomas exotoxin
US10556015B2 (en) 2014-10-24 2020-02-11 Criteo S.A. Lysosomal targeting of enzymes, and uses thereof
TWI752907B (zh) 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
CN107849131A (zh) 2015-07-06 2018-03-27 瑞泽恩制药公司 多特异性抗原结合分子及其用途
HK1253529A1 (zh) 2015-11-06 2019-06-21 Biomarin Pharmaceutical Inc. 用於检测中和溶酶体酶的摄取的抗体或其它因子的基於细胞的测定
RU2751235C2 (ru) * 2016-02-24 2021-07-12 Байомарин Фармасьютикал Инк. Терапевтические слитые белки направленного действия на основе лизосомных ферментов, соответствующие составы и их применения
SG11201808176TA (en) 2016-04-15 2018-10-30 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
CL2016003282A1 (es) 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
EP3635009A1 (en) 2017-06-07 2020-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
SG11202002730XA (en) 2017-10-02 2020-04-29 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes
IL322464A (en) 2018-02-07 2025-09-01 Regeneron Pharma Methods and compositions for administering therapeutic protein
CA3092961A1 (en) * 2018-03-09 2019-09-12 Avrobio, Inc. Compositions and methods for treating parkinson's disease
BR112020021962A2 (pt) 2018-04-30 2021-01-26 Amicus Therapeutics, Inc. construtos para terapia gênica e métodos de uso
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
EP3802619A1 (en) 2018-06-08 2021-04-14 F. Hoffmann-La Roche AG Peptidic linker with reduced post-translational modification
US11097015B2 (en) 2018-10-10 2021-08-24 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
AU2019381803A1 (en) * 2018-11-16 2021-06-10 AskBio Inc. Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal targeting sequence
WO2021072372A1 (en) * 2019-10-10 2021-04-15 Amicus Therapeutics, Inc. Variant igf2 constructs
WO2021133822A1 (en) 2019-12-24 2021-07-01 Juvena Therapeutics,Inc. Regenerative polypeptides and uses thereof
WO2021183895A1 (en) 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
CA3223707A1 (en) 2021-06-21 2022-12-29 Hanadie Yousef Regenerative polypeptides and uses thereof
WO2022271981A2 (en) 2021-06-23 2022-12-29 Lycia Therapeutics, Inc. Bifunctional compounds containing igf-2 polypeptides
CN117343197A (zh) * 2021-10-15 2024-01-05 中山大学 重组融合抗体
KR20250160369A (ko) * 2023-01-27 2025-11-12 리제너론 파마슈티칼스 인코포레이티드 변형된 랩도바이러스 당단백질 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122042A2 (en) * 2011-03-04 2012-09-13 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
AUPN674895A0 (en) 1995-11-23 1995-12-14 Women's And Children's Hospital Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
DE10035433C2 (de) 2000-07-20 2002-07-18 Tuma Wolfgang Schonende Hochanreicherung von fetalen Zellen aus pripherem Blut und Verwendung derselben
ES2300439T3 (es) 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
CA2463473A1 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Targeted therapeutic proteins
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
EP1514106A4 (en) 2002-05-29 2007-05-09 Zystor Therapeutics Inc TARGETED THERAPEUTIC PROTEINS
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CN1922313B (zh) 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
US7678371B2 (en) 2005-03-04 2010-03-16 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
HRP20170698T1 (hr) 2008-05-07 2017-09-22 Biomarin Pharmaceutical Inc. Lizosomski usmjereni peptidi i njihove uporabe
US8697654B2 (en) * 2008-12-18 2014-04-15 E I Du Pont De Nemours And Company Peptide linkers for effective multivalent peptide binding
US9029530B2 (en) 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
EP2475376B1 (en) * 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
MX362176B (es) 2010-06-25 2019-01-07 Amcor Rigid Plastics Usa Llc Sistema de depuracion de oxigeno para un recipiente.
MX2013000324A (es) * 2010-06-25 2013-02-01 Shire Human Genetic Therapies Tratamiento del sindrome de sanfilippo tipo b.
WO2012088461A2 (en) * 2010-12-23 2012-06-28 Biogen Idec Inc. Linker peptides and polypeptides comprising same
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
WO2012122477A1 (en) * 2011-03-10 2012-09-13 Novozymes A/S Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
HUE039334T2 (hu) 2012-11-27 2018-12-28 Biomarin Pharm Inc Célzott terápiás lizoszómális enzim fúziós fehérjék és azok alkalmazásai

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122042A2 (en) * 2011-03-04 2012-09-13 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same

Also Published As

Publication number Publication date
HK1216026A1 (en) 2016-10-07
US20160031964A1 (en) 2016-02-04
MX367024B (es) 2019-08-02
ES2729997T3 (es) 2019-11-07
MX2019009191A (es) 2019-10-09
WO2014085621A1 (en) 2014-06-05
IL238824A0 (en) 2015-06-30
IL272854B (en) 2021-07-29
HRP20190918T1 (hr) 2019-09-20
JP2016505539A (ja) 2016-02-25
LT3115372T (lt) 2019-06-25
BR112015012152A2 (pt) 2017-08-15
US20190225666A1 (en) 2019-07-25
AU2013352184A1 (en) 2015-06-04
AU2013352184B2 (en) 2018-05-31
KR20150088317A (ko) 2015-07-31
PL3115372T3 (pl) 2019-09-30
RU2680581C2 (ru) 2019-02-22
PT3115372T (pt) 2019-06-12
MX2015006644A (es) 2015-08-10
US9771408B2 (en) 2017-09-26
MX377150B (es) 2025-03-07
CY1122555T1 (el) 2021-01-27
CL2015001371A1 (es) 2015-10-09
ES2679374T3 (es) 2018-08-24
US9834587B2 (en) 2017-12-05
DK3115372T3 (da) 2019-06-11
IL272854A (en) 2020-04-30
IL262976A (en) 2018-12-31
US20220127326A1 (en) 2022-04-28
KR20220047892A (ko) 2022-04-19
EP2925776B1 (en) 2018-05-30
SI3115372T1 (sl) 2019-08-30
US9376480B2 (en) 2016-06-28
CN104822701B (zh) 2018-09-21
HUE039334T2 (hu) 2018-12-28
US9834588B2 (en) 2017-12-05
IL262976B (en) 2020-02-27
US20160039900A1 (en) 2016-02-11
IL238824B (en) 2018-11-29
US10301369B2 (en) 2019-05-28
HRP20181351T1 (hr) 2018-11-02
DK2925776T3 (en) 2018-09-03
HUE043679T2 (hu) 2019-09-30
RS58916B1 (sr) 2019-08-30
EP3115372A1 (en) 2017-01-11
AR093626A1 (es) 2015-06-17
PT2925776T (pt) 2018-07-30
CN104822701A (zh) 2015-08-05
TW201827468A (zh) 2018-08-01
CA2892146A1 (en) 2014-06-05
US20170355744A1 (en) 2017-12-14
JP2019206556A (ja) 2019-12-05
TW201431884A (zh) 2014-08-16
ZA201503509B (en) 2016-11-30
US20160031963A1 (en) 2016-02-04
RU2015125491A (ru) 2017-01-10
US11254725B2 (en) 2022-02-22
JP6831176B2 (ja) 2021-02-17
KR20230054482A (ko) 2023-04-24
US20140161788A1 (en) 2014-06-12
TWI626250B (zh) 2018-06-11
US9845346B2 (en) 2017-12-19
TWI711632B (zh) 2020-12-01
PL2925776T3 (pl) 2018-11-30
BR112015012152B1 (pt) 2023-04-25
JP6913719B2 (ja) 2021-08-04
EP2925776A1 (en) 2015-10-07
KR102385392B1 (ko) 2022-04-11
EP3115372B1 (en) 2019-03-06
KR20210070389A (ko) 2021-06-14
KR102521039B1 (ko) 2023-04-12
US20160031965A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
KR102262882B1 (ko) 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들
JP5627571B2 (ja) リソソーム標的化ペプチドおよびその使用
US20250388644A1 (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1232896A1 (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1232896B (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1216026B (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150626

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181126

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191022

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200925

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210303

GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210603

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210603

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210604

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20241128

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20250521

Start annual number: 5

End annual number: 5